Watch Q4 2026 guidance for adjusted EPS growth of only 0-5% YoY despite 18%+ revenue growth, suggesting margin headwinds from acquisition integration and higher interest expense. Monitor the Riverpoint Medical milestone payment and leverage trajectory.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $123.71entry
- T+1 · 6d ago −0.32%α −1.64% · $123.31
- T+4 · todayOpen
- T+5 · in 5h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Novanta reported Q3 2026 revenue of $305M (+23.1% YoY, +9.9% organic) and adjusted EPS of $1.05 (+20.7% YoY), both above consensus estimates of $301M and $0.97. The company raised full-year 2026 revenue guidance to $1,135M-$1,140M and adjusted EPS to $3.66-$3.71, reflecting strong momentum from the Riverpoint Medical acquisition and organic growth.
Key Financial Metrics
Key Facts
- Q3 2026 GAAP revenue $305M, up 23.1% YoY; organic revenue growth 9.9%
- Adjusted diluted EPS $1.05, up 20.7% YoY vs consensus $0.97 (beat)
- Adjusted EBITDA $80.3M, up 38.3% YoY; margin expanded 290 bps to 26.3%
- Customer bookings increased 29% YoY; backlog grew to $543M
- Full-year 2026 revenue guidance raised to $1,135M-$1,140M (prior $1,040M-$1,055M)
- Full-year 2026 adjusted EPS guidance raised to $3.66-$3.71 (prior $3.50-$3.65)
- Closed largest acquisition in company history (Riverpoint Medical) during Q3
- Net debt increased to $689M from net cash position of $121M at year-end 2025 due to acquisition financing
Financial Impact
Revenue beat consensus by $4M (1.3%); adjusted EPS beat consensus by $0.08 (8.2%); full-year guidance raised by ~$80M revenue and ~$0.11 EPS at midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Automation Enabling Technologies | $145.4M | +16.0% |
| Medical Solutions | $159.7M | +30.3% |
Risk Factors
- Net debt surged to $689M from a net cash position, increasing financial leverage and interest expense
- GAAP net income fell to $2M from $10.7M due to $23M in restructuring and acquisition costs
- Q4 adjusted EPS guidance of $0.91-$0.96 implies 0-5% YoY growth, a sharp deceleration from Q3's 21% growth
- Integration risk from the largest acquisition in company history
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-453760 |
| Document: novt-20261109.htm | 0001193125-26-453760 |
| Document: 0001193125-26-453760-index-headers.html | 0001193125-26-453760 |
| Document: 0001193125-26-453760-index.html | 0001193125-26-453760 |
| Document: 0001193125-26-453760.txt | 0001193125-26-453760 |
| 8-K Data (Synthetic) | 0001193125-26-453760 |
Track record
3 reports on NOVT
Filters
- Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $123.71 to $123.31 Now $114.40 −7.53% ▼ −0.32% −1.64% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $145.76 to $146.24 Now $114.40 −21.51% ▲ +0.33% +0.81% vs SPY
- Jun 29, 202620w ago S-3ASR Neutral 4/10 Entry $162.24 to $163.70 Now $114.40 −29.49% ▲ +0.90% +1.04% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers